Furthermore, SHP-2 inhibition resulted in a higher cell senescence and lower grade of tumor development in preclinical models of KRAS mutant NSCLC [120,121], with a synergistic effect observed when combining adagrasib with the anti-SHP-2 agent RMC-4550 [59]. Here, PTPN11 is linked to non-small cell lung carcinoma.